Endoceutics Revenue and Competitors

Québec, Canada

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Endoceutics's estimated annual revenue is currently $10.5M per year.(i)
  • Endoceutics's estimated revenue per employee is $201,000

Employee Data

  • Endoceutics has 52 Employees.(i)
  • Endoceutics grew their employee count by -35% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15.3M76-27%N/AN/A
#2
$10.5M52-35%N/AN/A
#3
$318.8M15867%N/AN/A
#4
$42M2098%N/AN/A
#5
$13.5M6710%N/AN/A
#6
$4.4M22-19%N/AN/A
#7
$4.6M23-4%N/AN/A
#8
$20.5M10240%N/AN/A
#9
$40.8M20368%N/AN/A
#10
$40.8M20368%N/AN/A
Add Company

EndoCeutics est une compagnie pharmaceutique privée, de niveau mondial, spécialisée dans le segment de la santé de la femme et la prévention ou traitement de certains cancers sensibles aux hormones. EndoCeutics a développé des indications ou opportunités ciblant des besoins non comblés dans la santé de la femme mais également de l'homme, y compris les traitements pour le cancer du sein et de la prostate, l'hypogonadisme, l'endométriose et les symptômes de la ménopause tels que les bouffés de chaleur, la prévention de l'ostéoporose ainsi que la prévention du cancer du sein, l'atrophie des muscles et la maladie de l'Alzeihmer. menopause, santé, santé de la femme, pharmaceutique

keywords:N/A

N/A

Total Funding

52

Number of Employees

$10.5M

Revenue (est)

-35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Endoceutics News

2022-04-17 - Endometriosis Market Size, Trends, Key Companies, Revenue Share Analysis, 2021–2028

... Pharmaceutical Co., Ltd., ElexoPharm, EndoCeutics, Gedeon Richter Plc., Myovant Sciences, Mayne Pharma Group Ltd., and Merck and Co.

2022-04-06 - Postmenopausal Vaginal Atrophy Therapeutics Market Share ...

Some of the Prominent/Emerging Players in Postmenopausal Vaginal Atrophy Therapeutics Market. Endoceutics Accord Healthcare Pfizer

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M5258%N/A
#2
$6.8M52N/AN/A
#3
$7.3M56-62%N/A
#4
$7.7M57-7%N/A
#5
$11.2M59-3%N/A